ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 479,40
-0,68%
Dow Jones
39 118,86
-0,12%
DAX
18 235,45
0,17%
Brent Oil
84,85
0,00%
Bitcoin
60 933,60
0,07%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Precigen Inc (PGEN)

  7. Precigen Inc (PGEN) Actualités

PGEN

Precigen (PGEN)

Precigen Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:PGEN
DateHeureSourceTitreSymboleSociété
03/06/202415h30PR Newswire (US)Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete ResponseNASDAQ:PGENPrecigen Inc
01/06/202401h06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PGENPrecigen Inc
28/05/202422h48Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:PGENPrecigen Inc
28/05/202422h44Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:PGENPrecigen Inc
23/05/202423h00PR Newswire (US)Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual MeetingNASDAQ:PGENPrecigen Inc
14/05/202423h23Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PGENPrecigen Inc
14/05/202423h19Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PGENPrecigen Inc
14/05/202422h05PR Newswire (US)Precigen Reports First Quarter 2024 Financial Results and Business UpdatesNASDAQ:PGENPrecigen Inc
08/05/202422h05PR Newswire (US)Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual MeetingNASDAQ:PGENPrecigen Inc
24/04/202416h20PR Newswire (US)Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual MeetingNASDAQ:PGENPrecigen Inc
24/04/202415h00PR Newswire (US)Actym Therapeutics Appoints Thomas Smart as CEONASDAQ:PGENPrecigen Inc
28/03/202421h05PR Newswire (US)Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11thNASDAQ:PGENPrecigen Inc
19/03/202421h05PR Newswire (US)Precigen Reports Full Year 2023 Financial Results and Business UpdatesNASDAQ:PGENPrecigen Inc
19/03/202412h27IH Market NewsUS Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices RetreatNASDAQ:PGENPrecigen Inc
12/03/202421h05PR Newswire (US)Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory PapillomatosisNASDAQ:PGENPrecigen Inc
05/03/202422h05PR Newswire (US)Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19thNASDAQ:PGENPrecigen Inc
27/02/202419h48Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:PGENPrecigen Inc
14/02/202422h00Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:PGENPrecigen Inc
06/02/202422h05PR Newswire (US)Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:PGENPrecigen Inc
18/01/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PGENPrecigen Inc
16/01/202414h05PR Newswire (US)Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European CommissionNASDAQ:PGENPrecigen Inc
08/01/202414h30PR Newswire (US)Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:PGENPrecigen Inc
29/12/202323h26Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:PGENPrecigen Inc
18/12/202322h05PR Newswire (US)Precigen to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:PGENPrecigen Inc
29/11/202322h05PR Newswire (US)Precigen to Participate in the JMP Securities Hematology and Oncology SummitNASDAQ:PGENPrecigen Inc
09/11/202322h55PR Newswire (US)Precigen Reports Third Quarter 2023 Financial Results and Progress of Clinical ProgramsNASDAQ:PGENPrecigen Inc
07/11/202322h05PR Newswire (US)Precigen to Participate in the Stifel 2023 Healthcare ConferenceNASDAQ:PGENPrecigen Inc
19/09/202322h05PR Newswire (US)Precigen to Participate in Upcoming Leading Investor and Industry ConferencesNASDAQ:PGENPrecigen Inc
09/08/202314h00PR Newswire (US)Precigen Reports Second Quarter and First Half 2023 Financial Results and Provides Update on Portfolio Prioritization and Capital Allocation Strategies to Extend Projected Cash Runway into 2025NASDAQ:PGENPrecigen Inc
09/08/202313h05PR Newswire (US)Precigen Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated ApprovalNASDAQ:PGENPrecigen Inc
 Showing the most relevant articles for your search:NASDAQ:PGEN

Dernières Valeurs Consultées

EU
RI
Pernod Ricard
EU
VIV
Vivendi
EU
GLE
Societe Generale
EU
MC
Lvmh Moet Hennessy Louis...
EU
ORA
Orange
EU
LR
Legrand
NASDAQ
AAPL
Apple
EU
AI
Air Liquide
NASDAQ
MSFT
Microsoft
NYSE
MRK
Merck
EU
DG
Vinci
NYSE
DIS
Walt Disney
EU
SGO
Cie de SaintGobain
NASDAQ
AMZN
Amazon.com
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés